HIV/AIDS Topics Vaccine Combo Demonstrates Protection Against HIV-like Virus in Monkey Study
- Details
- Category: HIV Vaccines
- Published on Friday, 03 July 2015 00:00
- Written by Beth Israel Deaconess
Administering a 2-part prime-boost vaccine prevented infection in half of a dozen rhesus monkeys repeatedly exposed to simian immunodeficiency virus (SIV), and antibody responses against viral envelope proteins appeared to be the key to protection, according to a study published in the July 2 advance edition of Science magazine.
Use of Truvada PrEP Not Linked to Depression in iPrEx Analysis
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 26 June 2015 00:00
- Written by Gladstone Institutes
Although depression-related symptoms were the most common severe adverse events in the iPrEx trial of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men, there was no association between depression and use of Truvada (tenofovir/emtricitabine) compared to placebo, according to a report in the June 16 edition of AIDS and Behavior.
Tenofovir Alafenamide Subdermal Implant Shows Promise for HIV PrEP in Beagle Study
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Sunday, 31 May 2015 00:00
- Written by Liz Highleyman
A sustained-release subdermal implant was able to maintain consistently high levels of tenofovir in cells with no adverse events in an animal study, offering proof-of-concept that an implant may be a good candidate for HIV pre-exposure prophylaxis, or PrEP, according to a study described in the April 20 edition of Antimicrobial Agents and Chemotherapy.
Prioritization is Crucial for the Success of PrEP, Model Confirms
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 10 June 2015 00:00
- Written by Gus Cairns
A mathematical model developed by researchers at Imperial College in London, based on what would happen if pre-exposure prophylaxis (PrEP) was introduced into a high-prevalence region in Kenya, shows that PrEP could be a "runaway success" or a "runaway failure," depending on a number of factors, according to a report in the March 27 edition of AIDS. These factors include adherence, whether new longer-lasting HIV drugs are used, the cost of drugs, and the overall efficiency of distribution.
Truvada PrEP Causes Only Minimal Bone Loss, Raltegravir Easier on Bones than PIs
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 28 May 2015 00:00
- Written by Liz Highleyman
Use of tenofovir/emtricitabine (Truvada) for HIV pre-exposure prophylaxis (PrEP) was associated with a small decrease in bone mineral density that stabilized after the first 6 months, according to study findings reported in the April 23 edition of Clinical Infectious Diseases. Related research showed that HIV-positive people starting an antiretroviral regimen containing the integrase inhibitor raltegravir (Isentress) experienced less bone loss than those taking protease inhibitors.
Web Design and Development by